Riku Kivisaari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Riku Kivisaari has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Aki Laakso
Department of Neurosurgery, Helsinki University Hospital, Finland; and
1 shared publication - Annamari Ranki
Department of Skin and Allergic Diseases, University of Helsinki, Helsinki University Central Hospital, P.O. Box 160, 00029 HUS Helsinki, Finland
1 shared publication Anu Lintulahti
Department of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, HUS FI-00029, Finland
1 shared publication- Elina Koskela
Department of Ophthalmology, Division of Neuro-ophthalmology, Helsinki University Central Hospital, Helsinki, Finland
1 shared publication Emilia Carlsson
Department of Dermatology and Allergology, University of Helsinki and Helsinki University Central Hospital, HUS FI-00029, Finland
1 shared publication- Ferzat Hijazy
Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland
1 shared publication
Latest Publications
- 31 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 84 (2) , 446-450
Transfusion Frequency of Red Blood Cells, Fresh Frozen Plasma, and Platelets During Ruptured Cerebral Aneurysm Surgery
- 31 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 84 (2) , 446-450
Transfusion Frequency of Red Blood Cells, Fresh Frozen Plasma, and Platelets During Ruptured Cerebral Aneurysm Surgery
- 1 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 83 (3) , 362-367
Eye Movement Abnormalities After a Ruptured Intracranial Aneurysm
- 1 March 2015
- Published by Elsevier in World Neurosurgery
- Vol. 83 (3) , 362-367
Eye Movement Abnormalities After a Ruptured Intracranial Aneurysm
- Open Access
- 25 October 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 52 (2) , 191-201
Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis
Copy number changes or reduced expression of the Neuron navigator 3 (NAV3) gene occurs in neuroblastomas and malignancies of epithelial or lymphoid origin. To elucidate whether NAV3 has a role in the tumorigenesis of nervous system tumors in general, we studied central and peripheral nervous system tumors for NAV3 copy number changes. In search for common tumorigenic denominators, we analyzed 113 central and peripheral nervous system tumors, including glial tumors (grades I–IV gliomas), medulloblastomas, and neuroblastomas. NAV3 copy number changes were studied by fluorescence in situ hybridization and correlated to survival analyses. To identify target genes of NAV3 deletion, NAV3 was silenced by siRNA in glioblastoma cell lines and gene expression profiles were analyzed by Agilent 4×44k dual-color microarrays. Selected upregulations were confirmed by immunohistochemistry and quantitative polymerase chain reaction. We found NAV3 amplifications to dominate in neuronally differentiated tumors, whereas glial tumors showed almost equal proportions of NAV3 deletion and amplification. However, Grade IV gliomas had more frequent NAV3 deletions than grades I–III gliomas. Silencing of NAV3 in glioma cell lines led to the upregulation of receptor genes associated with gonadotropin-releasing hormone and Jak-Stat signaling pathways. Kaplan–Meier analysis of the entire clinical tumor material showed association between NAV3 amplifications and favorable prognosis, as well as NAV3 deletions and unfavorable prognosis. With Cox regression model, a hazard ratio of 0.51 was observed for NAV3 amplifications and 1.36 for NAV3 deletions. We conclude that NAV3 may be a potential new prognostic biomarker and a potential therapeutic target.
- 25 October 2012
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 52 (2) , 191-201
Open AccessNeuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis
Copy number changes or reduced expression of the Neuron navigator 3 (NAV3) gene occurs in neuroblastomas and malignancies of epithelial or lymphoid origin. To elucidate whether NAV3 has a role in the tumorigenesis of nervous system tumors in general, we studied central and peripheral nervous system tumors for NAV3 copy number changes. In search for common tumorigenic denominators, we analyzed 113 central and peripheral nervous system tumors, including glial tumors (grades I–IV gliomas), medulloblastomas, and neuroblastomas. NAV3 copy number changes were studied by fluorescence in situ hybridization and correlated to survival analyses. To identify target genes of NAV3 deletion, NAV3 was silenced by siRNA in glioblastoma cell lines and gene expression profiles were analyzed by Agilent 4×44k dual-color microarrays. Selected upregulations were confirmed by immunohistochemistry and quantitative polymerase chain reaction. We found NAV3 amplifications to dominate in neuronally differentiated tumors, whereas glial tumors showed almost equal proportions of NAV3 deletion and amplification. However, Grade IV gliomas had more frequent NAV3 deletions than grades I–III gliomas. Silencing of NAV3 in glioma cell lines led to the upregulation of receptor genes associated with gonadotropin-releasing hormone and Jak-Stat signaling pathways. Kaplan–Meier analysis of the entire clinical tumor material showed association between NAV3 amplifications and favorable prognosis, as well as NAV3 deletions and unfavorable prognosis. With Cox regression model, a hazard ratio of 0.51 was observed for NAV3 amplifications and 1.36 for NAV3 deletions. We conclude that NAV3 may be a potential new prognostic biomarker and a potential therapeutic target.